Navigation Links
Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating!
Date:3/14/2012

WASHINGTON, March 14, 2012 /PRNewswire/ -- Apricus Biosciences, Inc. Chief Executive Officer, Dr. Bassam Damaj, (Nasdaq: APRI) (http://www.apricusbio.com) said in an interview with Charles Sample on CEONEWS.Tv  that Apricus Bio has transformed in 2012 from a clinical development company to an income-generating, hybrid specialty pharmaceutical firm.

The interview is at: http://www.ceonews.tv/apri

Damaj cited the company's proprietary NexACT® technology for drug deliver through the skin, its $25 million in cash, its recent acquisitions, its partnerships, and the expected sales in 2012 from several proprietary products as factors that he believes warrant a higher market valuation.

Apricus Bio is focused on sexual dysfunction, oncology, dermatology, autoimmune, pain, anti-infectives, diabetes and consumer healthcare.  The company describes NexACT® as a clinically validated multi-route drug delivery technology, utilizing patented, highly effective, novel "penetration enhancers" to dramatically improve absorption and bioavailability of drugs. Varying the concentration of the enhancer allows for local or systemic delivery of a drug, as desired.

Damaj noted that the company expects Abbott Laboratories to begin marketing Apricus Bio's NexACT® – based Vitaros® topical cream for erectile dysfunction (ED) in Canada this year. The topical application of Vitaros® helps to reduce side effects and enables men who cannot take, or do not do well with the existing ED drugs, to have a patient-friendly alternative.

In addition to its partnership with Abbott, Apricus Bio has established sales and distribution partnerships for its products with Warner Chilcott and Novartis, and the company will set up other partnerships as needed, Damaj said.&#
'/>"/>

SOURCE Apricus Biosciences, Inc.; CEONEWS.Tv
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
2. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
3. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
7. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
8. Neurocrine Biosciences, Inc. Prices Common Stock Offering
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
11. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... announced that the Company will release results for the ... before the opening of the U.S. financial markets. The ... at 8:30 a.m. ET to discuss results and highlights ... to be used during the call will be available ...
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
(Date:8/2/2014)... Dr. Ping Hu is a worldly ... in Medicine from the Capital Medical University in Beijing, ... Medical Microbiology from the University of London. She ... Sciences Center and finished her fellowship at the University ... was active both inside and outside of the classroom ...
(Date:8/2/2014)... August 02, 2014 When the Black Hat ... 2nd this year, one thing can be always counted on, ... known as fear, uncertainty and doubt. The run-up has ... this article published by Reuters on July 31st about ... mouse or keyboard to successfully infect a system with malware, ...
(Date:8/1/2014)... (PRWEB) August 02, 2014 The successful ... the stamping business of Guangdong FODAY Automobile Co.,LTD. As ... the company had already organized an excellent team to ... number of detailed, in-depth technical plans. The company’s vice ... were in the direct involvement of the specific arrangement ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2
... Reporter , TUESDAY, May 3 (HealthDay News) -- A structured ... blood sugar level more effectively than just receiving advice about ... data. After analyzing the results of 47 randomized ... periods of time was better at bringing blood sugar levels ...
... , TUESDAY, May 3 (HealthDay News) -- ... women, a new study shows. Duke University researchers ... completed a sexual functioning questionnaire before enrolling in a ... desire, arousal, orgasm, satisfaction, behavior, relationship, masturbation and sexual ...
... produces feelings of euphoria and emotional warmth has ... Clinical trials are testing Ecstasy in the treatment of ... magazine,s health section in February "Ecstasy as therapy: ... concern Ronald Cowan, M.D., Ph.D., associate professor of Psychiatry. ...
... (HealthDay News) -- Americans are feeling the pain of ... Mississippi has found a potential silver lining: Traffic ... of drunken driving -- as gas prices go ... short-term and intermediate-term effects on reducing traffic crashes," Guangqing ...
... and Boston Medical Center have found that by adding one ... hospital readmission costs by $579 million per year, or 83 ... target. These findings currently appear on the website of the ... of family physicians has fallen over the last decade due ...
... This release is available in Spanish . ... shelf to find the freshest salad greens with the latest ... Agriculture (USDA) scientists may prompt consumers to instead look for ... closest to the front. The study was led by ...
Cached Medicine News:Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 3Health News:Obese People Have Less Satisfying Sex Lives: Study 2Health News:Ecstasy associated with chronic change in brain function 2Health News:Researchers find increasing the number of family physicians reduces hospital readmissions 2Health News:Market lighting affects nutrients 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: